PolyNovo (ASX:PNV): Wound-Care Growth Continues Despite Market Pressure

Aditi Sarkar

11 August 2026 01:37 PM AEST

PolyNovo (ASX:PNV): Wound-Care Growth Continues Despite Market Pressure

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

PolyNovo (ASX:PNV) develops biodegradable wound-care technologies through its NovoSorb platform.
The company reported FY26 Revenue of $150 million, supported by growth in US commercial sales.
NovoSorb MTX sales increased during FY26 as the product expanded its market presence.
PolyNovo continues progressing regulatory activities and new product development initiatives.

PolyNovo has continued expanding its wound-care technology platform while navigating a period where Business growth and share market performance have moved in different directions. The company’s focus remains on commercialising NovoSorb products, expanding its US presence and progressing additional clinical and regulatory opportunities.

The company continues operating in a growth phase, with future performance dependent on sales expansion, Manufacturing execution and regulatory progress.

NovoSorb Technology Remains Core Platform

PolyNovo (ASX:PNV) develops biodegradable synthetic polymer technology through its NovoSorb platform.

The company’s flagship product, NovoSorb BTM (Biodegradable Temporising Matrix), is designed for severe burns and complex soft-tissue wounds by providing a temporary scaffold that supports tissue regeneration.

The technology is designed to provide an alternative approach to traditional wound management methods.

PolyNovo has expanded the platform through additional products targeting broader wound-care and reconstructive surgery applications.

FY26 Revenue Growth Supports Commercial Expansion

A key milestone for PolyNovo was its FY26 trading performance.

The company reported total revenue of $150 million for the year ended 30 June 2026, representing growth of 20.3% on a constant-currency basis.

Group commercial sales reached $138.4 million, increasing 16.7%.

The United States remained the largest market, contributing $102.1 million in commercial sales.

The results demonstrate continued commercial expansion, although profitability and Margin performance remain important focus areas.

NovoSorb MTX Expands Product Portfolio

PolyNovo (ASX:PNV) has continued developing its product portfolio beyond NovoSorb BTM.

NovoSorb MTX recorded commercial sales of $12.6 million during FY26, representing growth compared with the previous year.

The product expands the company’s exposure into additional wound-care and reconstructive surgery applications.

PolyNovo is also preparing NovoSorb SynPath for commercial launch, targeting chronic wounds including diabetic foot ulcers and venous leg ulcers.

Manufacturing Capacity Supports Future Growth

PolyNovo operates manufacturing facilities in Port Melbourne, Victoria.

The company has completed construction of a new manufacturing Facility , with validation activities progressing.

The expansion is designed to support future production requirements as commercial Demand increases.

Manufacturing capability remains an important Factor for PolyNovo as it continues expanding sales across international markets.

US Market Remains Strategic Focus

The United States remains the company’s largest commercial market.

PolyNovo has continued building its hospital customer base and expanding adoption of NovoSorb products.

The company is also progressing regulatory activities for broader US applications.

The potential submission of a Premarket Approval (PMA) application following completion of clinical requirements remains an important future milestone.

Financial Position and Cash Flow Improvement

PolyNovo (ASX:PNV) reported improved cash flow performance during FY26.

Operating Cash Flow reached $24 million, supported partly by a $3.5 million insurance payment related to a previous Research and Development facility incident.

Free cash flow improved to positive $10.4 million compared with negative $10.1 million in FY25.

Cash on hand increased to $35.4 million.

The improvement provides additional flexibility as the company continues investing in product development and commercial expansion.

Clinical and Regulatory Progress Remains Important

PolyNovo continues progressing clinical and regulatory activities across its product pipeline.

The company has finalised its Clinical Study Report for a US pivotal burns trial, supporting potential future regulatory submissions.

Regulatory timelines remain important as approval pathways influence the timing of broader product adoption.

Key Factors Investors May Monitor

Future developments for PolyNovo will focus on FY26 financial results, US sales growth, NovoSorb MTX adoption and progress towards additional regulatory milestones.

Investors will also monitor the commercial launch of NovoSorb SynPath and manufacturing performance at the expanded facility.

The company’s ability to convert revenue growth into sustainable profitability will remain a key measure.

Risks and Challenges

PolyNovo faces risks associated with medical device regulation, commercial adoption and manufacturing execution. While revenue growth has continued, the company remains dependent on expanding hospital adoption and maintaining sales momentum.

Regulatory approval timelines can change, and reimbursement conditions in key markets may influence commercial outcomes. The company also remains exposed to currency movements due to international sales and ongoing Investment requirements.

Looking Ahead

PolyNovo is entering its next growth phase with an expanded product portfolio, improved cash flow position and continued focus on international commercialisation.

The company’s future progress will depend on maintaining US sales growth, successfully launching new products and advancing regulatory pathways.

For PolyNovo (ASX:PNV), converting its technology platform into broader global adoption will remain the central objective.

Conclusion

PolyNovo has continued building its wound-care technology business through revenue growth, product expansion and progress across clinical programs.

The company’s FY26 performance demonstrated commercial momentum, although market sentiment has remained cautious due to profitability and execution considerations.

Future performance will depend on sales expansion, regulatory progress and the ability to sustain growth while improving financial outcomes.

FAQs

Q: What does PolyNovo do?

A:PolyNovo develops biodegradable wound-care technologies through its NovoSorb platform, including products used in burns and complex soft-tissue wounds.

Q: What is NovoSorb BTM?

A:NovoSorb BTM is PolyNovo’s flagship biodegradable matrix product designed to support tissue regeneration in severe wound-care applications.

Q: How much revenue did PolyNovo report in FY26?

A:PolyNovo reported total revenue of $150 million for FY26.

Q: What is PolyNovo’s key growth market?

A:The United States is PolyNovo’s largest commercial market and remains a key focus area for expansion.

Q: What are the key risks for PolyNovo?

A:Key risks include regulatory approval timelines, healthcare adoption, manufacturing execution, reimbursement conditions and currency movements.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.